"Erectile Function After PCI in MI and Non-MI Patients"
The goal of this observational study is to assess changes in patients' erectile function after percutaneous coronary intervention (PCI) using a standard IIEF (International Index of Erectile Function) questionnaire at 1, 3, and 6 months post-PCI. By doing this, we try to compare patients' responses to PCI after having a heart attack and stable angina to see the real effect of myocardial infarction on erectile function status in the long term by comparing it with a very similar group.
Erectile Disfunction, Coronary Artery Disease (CAD), Diabete Mellitus, Anxiety, Depression and Quality of Life
About this study
The goal of this observational study is to assess changes in patients' erectile function after percutaneous coronary intervention (PCI) using a standard IIEF (International Index of Erectile Function) questionnaire at 1, 3, and 6 months post-PCI. By doing this, we try to compare patients' responses to PCI after having a heart attack and stable angina to see the real effect of myocardial infarction on erectile function status in the long term by comparing it with a very similar group.
Primary outcomes
Change in erectile function score after percutaneous coronary intervention (PCI) (Baseline (post-recovery from PCI) to 6 months follow-up])
Eligibility information
Inclusion Criteria
* Male patients aged 30-75 years
* Undergoing successful percutaneous coronary intervention (PCI) for one of the following:
* Acute myocardial infarction (Group 1)
* Stable angina (Group 2)
* Hemodynamically stable after the PCI procedure
* Survival of the index hospitalization
* Ability to provide written informed consent
* Sexually active within the 3 months prior to enrollment
* Willingness and ability to complete follow-up visits and questionnaires at:
* Baseline (post-PCI recovery)
* 3 months
* 6 months Exclusion Criteria
* Known malignancy (active or recently treated)
* Neurological disorders affecting erectile function, including:
* Spinal cord injury
* Multiple sclerosis
* Parkinson's disease
* Uncontrolled diabetes mellitus (HbA1c \> 9%)
* Presence of more than two chronic systemic diseases, such as:
* Severe renal disease
* Severe hepatic disease
* Severe pulmonary disease
* Polypharmacy, defined as chronic use of more than three daily medications
* Absence of sexual activity or lack of a sexual partner
* Refusal or inability to provide informed consent or complete study questionnaires
* Severe psychiatric illness interfering with study participation
* Endocrine disorders, including:
* Untreated hypogonadism
* Thyroid disease
* Major post-PCI complications preventing participation, including:
* Reinfarction
* Stroke
* Heart failure
Study locations
The Hospital of Kirikkale Univerity Faculty of Medicine, Kirikkale, 71450 Turkey (Türkiye)
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-13.